CN1104625A - Chromium, copper and manganese lactates and their productions and applications - Google Patents
Chromium, copper and manganese lactates and their productions and applications Download PDFInfo
- Publication number
- CN1104625A CN1104625A CN 94102555 CN94102555A CN1104625A CN 1104625 A CN1104625 A CN 1104625A CN 94102555 CN94102555 CN 94102555 CN 94102555 A CN94102555 A CN 94102555A CN 1104625 A CN1104625 A CN 1104625A
- Authority
- CN
- China
- Prior art keywords
- calcium lactate
- chromium
- lactates
- preparation technology
- copper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000011651 chromium Substances 0.000 title claims abstract description 41
- 229910052804 chromium Inorganic materials 0.000 title claims abstract description 35
- 239000010949 copper Substances 0.000 title claims abstract description 22
- 229910052802 copper Inorganic materials 0.000 title claims abstract description 17
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 title claims description 33
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title claims description 15
- KSNGEYQWLMRSIR-UHFFFAOYSA-L 2-hydroxypropanoate;manganese(2+) Chemical class [Mn+2].CC(O)C([O-])=O.CC(O)C([O-])=O KSNGEYQWLMRSIR-UHFFFAOYSA-L 0.000 title description 2
- 238000004519 manufacturing process Methods 0.000 title description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 32
- 239000001527 calcium lactate Substances 0.000 claims abstract description 32
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 32
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 32
- 239000011572 manganese Substances 0.000 claims abstract description 19
- 239000011573 trace mineral Substances 0.000 claims abstract description 15
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 15
- 229910052748 manganese Inorganic materials 0.000 claims abstract description 14
- GRWVQDDAKZFPFI-UHFFFAOYSA-H chromium(III) sulfate Chemical compound [Cr+3].[Cr+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRWVQDDAKZFPFI-UHFFFAOYSA-H 0.000 claims abstract description 13
- 229910000365 copper sulfate Inorganic materials 0.000 claims abstract description 13
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 claims abstract description 13
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 13
- 150000003893 lactate salts Chemical class 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 229910017053 inorganic salt Inorganic materials 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 23
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 22
- 238000005516 engineering process Methods 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 19
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 12
- 239000004310 lactic acid Substances 0.000 claims description 11
- 235000014655 lactic acid Nutrition 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 230000036571 hydration Effects 0.000 claims description 4
- 238000006703 hydration reaction Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 238000003828 vacuum filtration Methods 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000004176 ammonification Methods 0.000 claims description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 235000015097 nutrients Nutrition 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 3
- 201000011510 cancer Diseases 0.000 abstract description 3
- 150000003839 salts Chemical class 0.000 abstract description 2
- 239000002131 composite material Substances 0.000 abstract 1
- 125000003745 glyceroyl group Chemical group C(C(O)CO)(=O)* 0.000 abstract 1
- 229940099596 manganese sulfate Drugs 0.000 abstract 1
- 235000007079 manganese sulphate Nutrition 0.000 abstract 1
- 239000011702 manganese sulphate Substances 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229940001447 lactate Drugs 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 4
- DYROSKSLMAPFBZ-UHFFFAOYSA-L copper;2-hydroxypropanoate Chemical compound [Cu+2].CC(O)C([O-])=O.CC(O)C([O-])=O DYROSKSLMAPFBZ-UHFFFAOYSA-L 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 2
- 229910021556 Chromium(III) chloride Inorganic materials 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 229960000359 chromic chloride Drugs 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002696 manganese Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 1
- 108700024123 Arginases Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- -1 blood pressure Chemical compound 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- UGWKCNDTYUOTQZ-UHFFFAOYSA-N copper;sulfuric acid Chemical compound [Cu].OS(O)(=O)=O UGWKCNDTYUOTQZ-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 231100000652 hormesis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229940050168 zinc lactate Drugs 0.000 description 1
- 235000000193 zinc lactate Nutrition 0.000 description 1
- 239000011576 zinc lactate Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The lactates of Cr, Cu and Mn for supplementing the trace elements to human body has a chemical formula Me (C3H5O3)x, where Me may be Cr3+, Cu2+ or Mn2+ and x is 3,2, or 2 respectively. The inorganic salts of Cr, Cu and Mn and calcium lactate are used as raw materials with the ratio of inorganic salt: calcium lactate=1:1.2-1.5; chromium sulfate: calcium lactate=1:1.5-1.5; copper sulfate: calcium lactate=1:1.2-1.25; manganese sulfate: calcium lactate=1:1.25=1.4. The composite nutrient prepared with said lactates can prevent and cure cancer, cardiovascular disease and diabetes mellitus.
Description
The present invention relates to a kind of lactic acid salt and relate in particular to a kind of Chromic lactate, copper, manganese salt and preparation technology and purposes.
At present, along with the raising of science and technology development and people's living standard, trace element role in the intravital physiological activity of people causes the particularly attention of medical circle and nutrition educational circles of people more.The vital role that calcium, iron, zinc are risen in person's physiological processes is for most of well-known, the anti-cancer that chromium, copper, manganese etc. are play a part in the human physiological activity, anticancer and prevent and treat the very big interest that cardiovascular disorder causes medical circle and other field scientist equally.At the end of the fifties, propositions such as Mertz 3 valency chromium are center activeconstituentss of glucose tolerance factor.People such as Mertz had summed up the physiological function of 3 valency chromium in 1969: (1) animal lacks chromium and can cause sugar tolerance impaired or develop into diabetes, hyperlipidemia, arteriosclerosis and the lost of life.Mend chromium the effect that reverses above-mentioned phenomenon is arranged; (2) 3 valency chromium can and Regular Insulin and mitochondrial membrane acceptor between form ternary complex and promote Regular Insulin to play a role (" practical diabetology, Jiang Guoyan, People's Health Publisher, 92 years first versions, 123 pages).Studies have shown that in a large number both at home and abroad over more than 30 year; Chromium is normal carbohydrate metabolism and the essential trace element of lipid metabolism, and chromium deficiency and type II diabetes, cardiovascular and cerebrovascular diseases have substantial connection in the diet.Punsar has carried out follow-up study in 10 years to two geographic residents of the higher water of the very low water of Finland's long-term drinking chromium content and long-term drinking chromium content, resident's Incidence of CHD of the low chromium water of proof long-term drinking and mortality ratio all are higher than resident (" trace element chromium and coronary heart disease and the research of blood fat literary composition system " Cui Jinshan, the Liu Daorong etc. that drink high chromium water, the whole nation the 4th medical science trace element academic meeting paper collection, the 96th page).After Rialos in 1981 and Albrink mend chromium to hyperlipemic patients with chromium chloride, experimenter's serum triglyceride reduces, HDL-C increases, with the comfort group statistical significance is arranged relatively, Glinsmann supplies the chromium of 180-1000ug every day for the diabetics with chromium trichloride, 75% human glocose tolerance is obviously improved behind the some months, 25% human glocose tolerance curve slightly reduces, Anderson supplies 200ug chromium with chromium chloride to 26 normal the elderlys every day from diet, its sugar tolerance is carried out the double blinding crossing research, three months is a course of treatment, result wherein sugar tolerance sufferer sugar tolerance obviously improves (" practical diabetology " Jiang Guoyan, People's Health Publisher's in September, 92 first version, 1238 pages).The loyal loyalty of Huaxi Medical Univ's beam in 1988 adds with trivalent chromium the 12 not good enough diabeticss of routine insulinize effect treats, patient's fasting plasma glucose, glycolated hemoglobin, total cholesterol obviously improve after 2 months, (Journal of West China University of Medical Sciences, 1988,19(4), 413); Beijing Hospital Jiang state man of virtue and ability etc. proves in clinical study: trivalent chromium is the good nutritious supplementary of type II diabetes people, mend the biological activity that chromium can increase Regular Insulin for the type II diabetes people, improve patient's sugar tolerance, (practical diabetology, 130-139 page or leaf Jiang Guoyan chief editor in October, 1992 People's Health Publisher).
World-renowned medical science trace element expert United States Medical Doctor H.A Schroeder (Schroedler) prophesy: plumbous few people in people that chromium is many in the tissue and the body, might live 90 to 110 years old.The U.S.'s 3 valency chromium on probation are prevented and treated arteriosclerosis in recent years, obtained effect preferably, curative effect was obvious after part diabetic subject mended chromium, insulin dosage greatly reduced after the type II diabetes patient mended chromium, someone asserts that this effect of chromium will be opened up the prospect that a people gets a good chance of for treatment of diabetes.
Trace copper has biocatalysis to many important enzymes and hormone in the body in the human body, and world-renowned nutritionist Kai Lewei thinks: it is uniquely to impel cholesterol, blood pressure, uric acid to raise simultaneously and influence sugar tolerance and cause the factor of heart abnormality that health lacks copper.Beijing China-Japan Friendship Hospital with the copper agent with and blood stagnation resolvation Chinese medicine form prescription and be applied to clinical cancer patient inhibiting rate and reach 76.6% survival time and prolong 44.6%, (93 years whole nations the 4th medical science trace element academic meeting paper collection, the 187th page).
Trace element manganese is the composition branch of arginase in the human body in the body, there are hundred kinds of enzymes can be in the body by manganese activated, the health manganese deficiency can cause that the DNA conformation changes, thereby reduce its accuracy of transcribing and cause fetal anomaly, patients with osteoporosis all is accompanied by manganese deficiency mostly, U.S.'s physiologist's Saltman is pointed out: normal skeletonization needs a kind of material that is called mucopolysaccharide, and the formation of mucopolysaccharide must be participated in by manganese, the manganese deficiency osseous tissue just can not synthesize well, and the long volt of the grandson of Chinese Medical Sciences University waits damaged at bone, bone is replanted, proof in the practice of allogenic bone transplantation clinical operation: operation back manganese supplement helps the healing of wound.Manganese also has substantial connection with functionss of hormones such as glucocorticosteroid, sexual hormoue and S-hydroxy-tryptamines, draws so the health manganese deficiency also may cause sexual function to decline.The Li Hanfang of Shanghai Medical Univ etc. proves with experimentation on animals, trace element chromium, copper, manganese, food rich in fat caused that fatty liver and cardiovascular disorder, arteriosclerosis improve significantly and therapeutic action.(the 39th page of the whole nation the 3rd medical science trace element academic paper collection).
At present, to replenishing of trace element chromium in the human body, copper, manganese, the medical worker adopts is the inorganic salt of these elements such as chromium trichloride, copper sulfate, manganous sulfate etc., and these all belong to strong acid weak base salt, and it is low to exist (1) bioavailability; (2) the strong acid root has hormesis to mucous membrane; (3) hydrolysis easily taking place generates precipitation, thereby poor stability.
The object of the present invention is to provide and a kind ofly very easily be absorbed by the body, toxic side effect is very little, in time replenish chromium, copper, manganese microelement in the human body, play anti-cancer, anticancer especially the elderly's cardiovascular disorder and diabetes are had treat and Chromic lactate, copper, manganese salt series products and the preparation technology and the purposes of prophylactic effect.
Technical scheme of the present invention is achieved in that
A kind of lactates that is used for replenishing body trace element chromium, copper, manganese, its chemical formula is Me(C
5H
5O
6), structural formula is:
Me is respectively Cr
3, Cu
2, Mn
2, X is respectively 3,2,2.
The preparation technology of above-mentioned lactates is for getting the raw materials ready, give heat, mixes, filtration, crystallization, it is characterized in that adopting containing Cr
1, Cu
2, Mn
2Ionic inorganic salt and calcium lactate (C
(C
3H
5O
)
Perhaps lactic acid (HC
3H
5O
3) be raw material, its proportioning is 1: the 1.2-1.5(weight ratio) calcium lactate is hydration calcium lactate (C
(C
H
5O
3)
.5H
2O), contain Cr
1, Cu
2, Mn
2The ionic inorganic salt are preferably chromium sulphate, copper sulfate, its proportioning of manganous sulfate:
Chromium sulphate: calcium lactate=1: 1.3-1.5;
Copper sulfate: calcium lactate=1: 1.2-1.25;
Manganous sulfate: calcium lactate=1: 1.25-1.4;
Chromium sulphate is the hydration chromium sulphate, and copper sulfate is hydrated copper sulfate, and manganous sulfate is an anhydrous manganese;
Mixing temperature is 50-60 ℃;
Be filtered into vacuum filtration;
It is chromic anhydride that the preparation technology of Chromic lactate can also adopt chromic anhydride, S-WAT, sulfuric acid, lactic acid to make its proportioning of raw material: lactic acid: S-WAT: sulfuric acid=1: (2.5-3.5): (1.8-2.5): (1.47-2.22);
Its preparation technology be with the chromic anhydride aqueous solution with sulfuric acid acidation after again with S-WAT reaction, ammonification water generates precipitation, filter, use the pure water washing precipitate, add the lactic acid reaction, then reaction solution is concentrated, crystallization, dry.
The amount that adds ammoniacal liquor is controlled by PH=8-9.
Reaction principle of the present invention is:
Positively effect of the present invention is: raw material is easy to get, preparation technology is simple, cost is low, because the effect of lactate, this product very easily is absorbed by the body, the bioavailability height carries out in time replenishing and then reaches the effect of anticancer, anti-cancer, treatment cardiovascular disorder and diabetes to chromium, manganese, copper, deficient patients in the body.
Below in conjunction with embodiment the present invention is further described in detail:
Embodiment 1, take by weighing chromium sulphate 200g and be dissolved in the pure water of 1000ml, take by weighing calcium lactate 260g and be dissolved in the hot water of 1000ml, (chromium sulphate: calcium lactate=1: the 1.3(weight ratio)), in the time of 60 ℃ two liquid hybrid reactions are placed 3 hours final vacuums and filter, filtrate is concentrated into dried Chromic lactate crystallization.
Embodiment 2, its raw material and preparation technology are with embodiment 1, wherein
Chromium sulphate: calcium lactate=1: the 1.4(weight ratio).Temperature of reaction is 50 ℃
Embodiment 3, and its raw material and preparation technology are with embodiment 1, wherein
Chromium sulphate: calcium lactate=1: the 1.5(weight ratio).
Embodiment 4, take by weighing chromic anhydride 200g, in the beaker of 3000ml, adding distil water 2000ml, stirring and dissolving is measured vitriol oil 170ml with graduated cylinder, under the stirring that does not stop, slowly add in the chromic anhydride aqueous solution, add S-WAT 380g then in batches, be warming up to gradually and boil, and boiled 15 minutes, be cooled to temperature and be not higher than 50 ℃, slow dropping ammonia control solution pH value is 8 under the stirring that does not stop, and places 24 hours, vacuum filtration, precipitation is washed till no Cr with pure water
6+, the greyish-green precipitation of cleaning being dissolved in the lactic acid solution of 1700g40% and reacting, reaction solution is concentrated into dried in water-bath, must deceive the Chromic lactate crystallization of purple.Reactant ratio is:
Chromic anhydride: lactic acid: S-WAT: sulfuric acid=1: 3.4: 1.9: 1.5, (weight ratio).
Embodiment 5, its raw material and preparation technology are with embodiment 4 wherein
Chromic anhydride: lactic acid: S-WAT: sulfuric acid=1: 3: 1.8: the 2.22(weight ratio).
Embodiment 6, its raw material and preparation technology are with embodiment 4 wherein
Chromic anhydride: lactic acid: S-WAT: sulfuric acid=1: 2.5: the 2.2(weight ratio).
Embodiment 7, take by weighing copper sulfate 200g, calcium lactate 240g(copper sulfate: calcium lactate=1: 1.2) be dissolved in respectively in the pure water of 1000ml, give heat and after 60 ℃ two liquid are mixed, placement is spent the night, and vacuum filtration then, filtrate condensing crystal promptly get the cupric lactate product.
Embodiment 8, take by weighing calcium lactate 250g and be dissolved in the pure water of 1000ml and be heated to 70 ℃, slowly with 200g solid sulphuric acid copper (copper sulfate: calcium lactate=1: 1.255) add mixing, place 5 hours final vacuums and filter, filtrate concentrates evaporate to dryness, promptly gets the crystal cupric lactate.
Embodiment 9, take by weighing 200g manganous sulfate 200g, calcium lactate 250g is dissolved in respectively in the 1000ml water, and (manganous sulfate: calcium lactate=1: 1.25) calcium lactate gives heat to 60 ℃, two liquid are mixed uniformly, and placement is spent the night, and filters, the filtrate evaporate to dryness promptly gets the crystal manganous lactate.
Embodiment 10, take by weighing the 260g calcium lactate and be dissolved in the 2000ml pure water, be heated to 60 ℃, the 200g manganous sulfate is under agitation slowly added, (manganous sulfate: calcium lactate=1: 1.3) placed 5 hours, filter, the filtrate evaporate to dryness promptly gets the manganous sulfate crystal.
Needs according to human body, utilize the biological synergetic effect of trace element, use Chromic lactate, cupric lactate, manganous lactate, zinc lactate, calcium lactate is formed compound nutrients, and is good by Beijing Tongren Hospital's afterreaction on probation, can regulate the balance of body trace element, increase the resistance against diseases of appetite, enhancing body, anticancer, give protection against cancer, prevent and treat atherosclerosis, to hypertension, cardiovascular and cerebrovascular diseases, diabetic subject can be hypoglycemic, reducing blood-fat, hypercholesterolemia, play the effect that nutrition is cured the disease.
Application examples 1, utilize Chromic lactate, cupric lactate, the compound nutrients of manganous lactate and auxiliary material preparation is tried out diabetes (II) patient, its fasting plasma glucose (FBS) is 10.1mmol/L before on probation, triglyceride (TG) 1.52mmol/L, EJG cholesterol (TC) is 5.12mmol/L, try out after two months, the result of laboratory test of above-mentioned every index is respectively 8.2mmol/L, 1.12mmol/L, 4.58mmol/L, and the shank edema disappears, patient continues the trial edition compound nutrients, after 5 months, be respectively 6.3mmol/L through chemically examining every index, 1.02mmol/L, 4.63mmol/L.
Application examples 2, try out tangible curative effect is also arranged suffering from the hyperlipidemia patient, patient's result of laboratory test before the trial edition compound nutrients is triglyceride (TG) 1.3mmol/L, cholesterol (TC) 4.73mmol/L, on probation after 4 months the above-mentioned every index of result of laboratory test be respectively 1.08mmol/L, 4.08mmol/L.
Application examples 3, high fat of blood patient chemically examine every index before the trial edition compound nutrients be blood fat (TG) 1.27mmol/L; Cholesterol (TC) 4.65mmol/L; The trial edition compound nutrients, after 3 months the above-mentioned every index of chemical examination be respectively 1.10, mmol/L, 4.51mmol/L.
Claims (8)
1, a kind of lactates that is used for replenishing body trace element chromium, copper, manganese, its chemical formula is Me (C
3H
5O
3)
x, structural formula is:
Me is respectively Cr
3+, Cu
2+, Mn
2+, X is respectively 3,2,2.
2, a kind of preparation technology of lactates as claimed in claim 1 is: getting the raw materials ready, give heat, stirring, filtration, crystallization, it is characterized in that adopting the inorganic salt and the calcium lactate that contain chromium, copper, mn ion is raw material, its weight ratio is inorganic salt: calcium lactate=1: 1.2-1.5, calcium lactate are the hydration calcium lactate.
3, the preparation technology of lactates according to claim 2 is characterized in that containing Cr
1, Cu
2, Mn
2The ionic inorganic salt are preferably chromium sulphate, copper sulfate, manganous sulfate
Its proportioning is: chromium sulphate: calcium lactate=1: 1.3-1.5;
Copper sulfate: calcium lactate=1: 1.2-1.25;
Manganous sulfate: calcium lactate=1: 1.25-1.4.
4, the preparation technology of lactates according to claim 3 is characterized in that described chromium sulphate is the hydration chromium sulphate, and copper sulfate is hydrated copper sulfate, and manganous sulfate is an anhydrous manganese;
5, the preparation technology of lactates according to claim 2, it is characterized in that mixing temperature is 50-60 ℃.
6, the preparation technology of lactates according to claim 2 is characterized in that the described vacuum filtration that is filtered into.
7, the preparation technology of lactates according to claim 2 is characterized in that adopting chromic anhydride, S-WAT, sulfuric acid, lactic acid to make its proportioning of raw material being
Chromic anhydride: lactic acid: S-WAT: sulfuric acid=1: (2.5-3.5): (1.8-2.5): (1.47-2.22);
Its preparation technology be with the chromic anhydride aqueous solution with sulfuric acid acidation after again with S-WAT reaction, ammonification water generates precipitation, filter, use the pure water washing precipitate, add the lactic acid reaction, then reaction solution is concentrated, crystallization, dry.
8, the preparation technology of lactates according to claim 6 is characterized in that the amount that adds ammoniacal liquor controlled by PH=8-9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94102555 CN1104625A (en) | 1994-03-21 | 1994-03-21 | Chromium, copper and manganese lactates and their productions and applications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 94102555 CN1104625A (en) | 1994-03-21 | 1994-03-21 | Chromium, copper and manganese lactates and their productions and applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1104625A true CN1104625A (en) | 1995-07-05 |
Family
ID=5030702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 94102555 Pending CN1104625A (en) | 1994-03-21 | 1994-03-21 | Chromium, copper and manganese lactates and their productions and applications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1104625A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003011263A3 (en) * | 2001-07-20 | 2003-12-18 | S K Entpr Gmbh | Use of a lactate salt for the treatment and prophylaxis of atherosclerosis |
| WO2004009070A1 (en) * | 2002-07-22 | 2004-01-29 | S.K. Enterprise Gmbh | Calcium lactate and whey permeate for lowering the triglyceride level |
| CN102781254A (en) * | 2009-12-22 | 2012-11-14 | 拉尔科营养品有限公司 | Organically chelated mineral composition and method for preparing same |
| CN107405320A (en) * | 2014-12-29 | 2017-11-28 | 麦提麦迪制药有限公司 | The pharmaceutical composition for including metal lactate for treating cancer |
| US10570066B2 (en) | 2014-04-17 | 2020-02-25 | Ralco Nutrition, Inc. | Agricultural compositions and applications utilizing mineral compounds |
-
1994
- 1994-03-21 CN CN 94102555 patent/CN1104625A/en active Pending
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003011263A3 (en) * | 2001-07-20 | 2003-12-18 | S K Entpr Gmbh | Use of a lactate salt for the treatment and prophylaxis of atherosclerosis |
| WO2004009070A1 (en) * | 2002-07-22 | 2004-01-29 | S.K. Enterprise Gmbh | Calcium lactate and whey permeate for lowering the triglyceride level |
| CN102781254A (en) * | 2009-12-22 | 2012-11-14 | 拉尔科营养品有限公司 | Organically chelated mineral composition and method for preparing same |
| CN102781254B (en) * | 2009-12-22 | 2015-11-25 | 拉尔科营养品有限公司 | Organically chelated mineral composition and method for preparing same |
| EP2515677A4 (en) * | 2009-12-22 | 2017-06-21 | Ralco Nutrition, Inc. | Organically chelated mineral compositions and methods thereof |
| US10696602B2 (en) | 2009-12-22 | 2020-06-30 | Ralco Nutrition, Inc. | Organically chelated mineral compositions and methods thereof |
| US11078127B2 (en) | 2009-12-22 | 2021-08-03 | Ralco Nutrition, Inc. | Organically chelated mineral compositions and methods thereof |
| US10570066B2 (en) | 2014-04-17 | 2020-02-25 | Ralco Nutrition, Inc. | Agricultural compositions and applications utilizing mineral compounds |
| CN107405320A (en) * | 2014-12-29 | 2017-11-28 | 麦提麦迪制药有限公司 | The pharmaceutical composition for including metal lactate for treating cancer |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koo et al. | Aluminum and bone disorders: with specific reference to aluminum contamination of infant nutrients. | |
| POPPER et al. | The clinical significance of the plasma vitamin A level | |
| CN1104625A (en) | Chromium, copper and manganese lactates and their productions and applications | |
| CN104223115B (en) | The new application of scale collagen polypeptide | |
| CN115786432A (en) | Method for preparing pigeon meat peptide by high-pressure homogeneous coupling low-frequency ultrasonic field auxiliary enzymolysis and application | |
| JP2983171B2 (en) | New method for producing picolinic acid-chromium composite | |
| CN102309513A (en) | Application of drug composition in preparation of drugs for treating hypertensive disease | |
| CN102049037A (en) | Application of ocean collagen peptide in process of preparing diabetes wound healing medicaments and foods | |
| CN1221268C (en) | Magnesium-calcium ion composite preparation and production precess thereof | |
| Fairhall et al. | The excretion of zinc in health and disease | |
| CN109331036A (en) | Application of polysaccharide iron in the preparation of drugs for the treatment of hyperphosphatemia | |
| CN101536788A (en) | Calcium supply oral liquid for old people | |
| CN1844164A (en) | A kind of preparation method and application of carboxymethyl chitosan calcium | |
| CN1225920A (en) | Method for preparing amino acid-magnesium chelate and use thereof | |
| MARBLE et al. | Studies of iron metabolism in a case of hemochromatosis | |
| CN1181205A (en) | Nutritus liquid containing active calcium | |
| CN1634069A (en) | Calcium, zinc and ferrum composite oral liquor and its preparing process | |
| RU2785115C1 (en) | Method for activating energy metabolism during the development of pathobiochemical processes in animals | |
| CN1476887A (en) | Medicine for curing vaginits and dermatosis and its preparation method | |
| CN1141945C (en) | Chinese medicine prepn for treating rheumatoid arthritis and its prepn | |
| CN106963779A (en) | A kind of production method of compound potassium dihydrogn phosphate | |
| CN1513458A (en) | Compound silver zinc sulfapyrimidine ointment, and its prepn. method | |
| Wisniak | Glycolic Ferment: The Work of Victor Barral and Raphaël Lépine | |
| CN119185196A (en) | Calcium-magnesium-zinc oral liquid and preparation method thereof | |
| CN113143960A (en) | Blood replenishing oral liquid for pets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |